New obesity drug candidate GUB014295 passes first safety check in small human study
NCT ID NCT06144684
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-stage study tested the safety and tolerability of a new drug called GUB014295 in 76 healthy adults who were lean, overweight, or obese. Participants received either the drug or a placebo as a single or multiple doses under the skin. The main goal was to check for side effects and how the drug moves through the body, not to treat or cure any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Quotient Sciences
Nottingham, NG11 6JS, United Kingdom
Conditions
Explore the condition pages connected to this study.